February 15, 2024 C-Path Launches Revamped Website to Enhance Collaborations in Drug Development Critical Path Institute (C-Path) today officially launched its newly revamped website, designed to further enhance collab...
February 1, 2024 FamilieSCN2A Partners with C-Path’s RDCA-DAP, Advancing Research Efforts for SCN2A-Related Disorders n a significant step to enhance research efforts for SCN2A-related autism and epilepsy, Critical Path Institute (C-Path) and Famil
May 31, 2023 CACNA1A Foundation to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development TUCSON, Ariz., May 31, 2023 — Critical Path Institute (C-Path) announced today that the CACNA1A Foundation, a parent-led nonprof
December 1, 2022 C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies TUCSON, Ariz., Dec. 1, 2022 — Critical Path Institute (C-Path) and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmac
November 2, 2022 C-Path and Eisai Data Sharing Collaboration to Include Lennox-Gastaut Syndrome Registry and Clinical Trial Data TUCSON, Ariz., Nov. 2, 2022 — Critical Path Institute (C-Path) and the Eisai Co., Ltd. (Eisai) today announced a joint collabora
June 7, 2022 C-Path and MitoAction Announce Data Sharing Agreement to Support Treatment Development in Mitochondrial Disease TUCSON, Ariz., June 7, 2022 — Critical Path Institute (C-Path) and MitoAction today announced a joint collaboration to incorpora
December 3, 2020 C-Path Selects Aridhia to Support Rare Disease Cures Accelerator-Data and Analytics Platform TUCSON, Ariz., December 3, 2020 — The Critical Path Institute (C-Path) today announced it has selected Aridhia to support
March 8, 2015 Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy August 3, 2015 Critical Path Institute Launches New Consortium Dedicated To Duchenne Muscular Dystrophy Tucson, Arizona – August
January 6, 2015 Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarker June 1, 2015 Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarke
April 2, 2014 Critical Path Institute Receives Grant to Accelerate Development of Tuberculosis Treatments